Mark Livingston Sells 21,303 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 21,303 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $25.50, for a total value of $543,226.50. Following the sale, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at $1,233,129. The trade was a 30.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Progyny Stock Down 2.2%

NASDAQ:PGNY opened at $24.83 on Friday. The company’s 50 day moving average is $21.21 and its 200-day moving average is $21.98. Progyny, Inc. has a 12 month low of $13.86 and a 12 month high of $27.25. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of 39.41, a P/E/G ratio of 2.00 and a beta of 1.29.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.06. The business had revenue of $313.35 million during the quarter, compared to the consensus estimate of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. Progyny’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. Research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PGNY has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on Progyny from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target (up from $26.00) on shares of Progyny in a report on Friday, August 8th. Raymond James Financial set a $28.00 price objective on shares of Progyny in a research note on Friday, August 8th. KeyCorp raised shares of Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 target price on the stock in a research report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

Institutional Trading of Progyny

A number of institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System raised its stake in shares of Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after purchasing an additional 457 shares in the last quarter. Leibman Financial Services Inc. raised its stake in shares of Progyny by 1.1% in the 2nd quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock valued at $1,011,000 after buying an additional 513 shares in the last quarter. Teza Capital Management LLC lifted its holdings in shares of Progyny by 5.4% during the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after acquiring an additional 516 shares during the period. Aristides Capital LLC boosted its position in shares of Progyny by 4.6% during the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after acquiring an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP increased its stake in Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after acquiring an additional 531 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.